Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 9506030 Compounds and methods for enhanced cellular uptake

Patent 9506030 was granted and assigned to Regulus Therapeutics on November, 2016 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

Regulus Therapeutics

0

Current Assignee

Regulus Therapeutics

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Balkrishen Bhat0

Date of Patent

November 29, 2016

0

Patent Application Number

142661270

Date Filed

April 30, 2014

0

Patent Citations Received

US Patent 11759532 mRNA targeting molecule comprising N-acetylgalactosamine binding polypeptide and preparation method therefor

US Patent 12005120 Galnac conjugated modified oligonucleotides as miR-122 inhibitor having HCV antiviral activity with reduced hyperbilirubinemia side-effect

0

US Patent 11932857 Immunostimulatory oligonucleotides

0

US Patent 11707528 Mannose-based mRNA targeted delivery system and use thereof

0

Patent Primary Examiner

Lawrence E Crane

0

Patent abstract

Described herein are conjugated modified oligonucleotides that are complementary to a target RNA. The conjugate facilitates cellular uptake of the modified oligonucleotide, resulting improved potency.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 9506030 Compounds and methods for enhanced cellular uptake

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool